Literature DB >> 1915747

Leishmania donovani: long-term culture of axenic amastigotes at 37 degrees C.

P S Doyle1, J C Engel, P F Pimenta, P P da Silva, D M Dwyer.   

Abstract

L. donovani promastigotes were subjected to heat treatment yielding an axenic amastigote stage which was long-term cultured at 37 degrees C. No differences were observed between the growth rates of axenic amastigotes and promastigotes. Flow cytometry-derived DNA histograms of axenic amastigotes and promastigotes were typical of exponentially growing cell populations. Moreover, axenic amastigotes were metabolically active as evidenced by the release of an immunoprecipitable extracellular acid phosphatase (SAcP) into their culture supernatant. Cell transformation was confirmed by transmission electronmicroscopic examination of thin sections and extended by fracture-flip survey which allowed differentiation of cell membranes. The ultrastructure and nanoanatomy of axenic amastigotes was identical to that of intracellular amastigotes. The production of large amounts of heat-shock axenic amastigotes suitable for biochemical and biological studies of differentiation in Leishmania donovani may have important implications in the development of prevention and/or treatment strategies.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1915747     DOI: 10.1016/0014-4894(91)90104-5

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  38 in total

1.  Leishmania major Hsp100 is required chiefly in the mammalian stage of the parasite.

Authors:  A Hübel; S Krobitsch; A Hörauf; J Clos
Journal:  Mol Cell Biol       Date:  1997-10       Impact factor: 4.272

Review 2.  The genetics of Leishmania virulence.

Authors:  Eugenia Bifeld; Joachim Clos
Journal:  Med Microbiol Immunol       Date:  2015-06-06       Impact factor: 3.402

3.  An axenic amastigote system for drug screening.

Authors:  H L Callahan; A C Portal; R Devereaux; M Grogl
Journal:  Antimicrob Agents Chemother       Date:  1997-04       Impact factor: 5.191

4.  Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis.

Authors:  L Soong; S M Duboise; P Kima; D McMahon-Pratt
Journal:  Infect Immun       Date:  1995-09       Impact factor: 3.441

5.  Developmental gene expression in Leishmania donovani: differential cloning and analysis of an amastigote-stage-specific gene.

Authors:  H Charest; G Matlashewski
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

6.  Fast high yield of pure Leishmania (Leishmania) infantum axenic amastigotes and their infectivity to mouse macrophages.

Authors:  Juliana Dias Costa; Renata Soares; Léa Cysne Finkelstein; Suzana Côrte-Real; Maria de Nazareth Meirelles; Renato Porrozzi
Journal:  Parasitol Res       Date:  2009-03-18       Impact factor: 2.289

7.  Comparison of the expression profiles of promastigotes and axenic amastigotes in Leishmania donovani using serial analysis of gene expression.

Authors:  Qiaoli Li; Yangxing Zhao; Bing Ni; Chenjiang Yao; Ying Zhou; Wangjie Xu; Zhaoxia Wang; Zhongdong Qiao
Journal:  Parasitol Res       Date:  2008-06-22       Impact factor: 2.289

8.  The co-chaperone SGT of Leishmania donovani is essential for the parasite's viability.

Authors:  Gabi Ommen; Mareike Chrobak; Joachim Clos
Journal:  Cell Stress Chaperones       Date:  2009-12-02       Impact factor: 3.667

9.  Cyclosporin A treatment of Leishmania donovani reveals stage-specific functions of cyclophilins in parasite proliferation and viability.

Authors:  Wai-Lok Yau; Thierry Blisnick; Jean-François Taly; Manuela Helmer-Citterich; Cordelia Schiene-Fischer; Olivier Leclercq; Jing Li; Dirk Schmidt-Arras; Miguel A Morales; Cedric Notredame; Daniel Romo; Philippe Bastin; Gerald F Späth
Journal:  PLoS Negl Trop Dis       Date:  2010-06-29

10.  Infectivity of Leishmania mexicana is associated with differential expression of protein kinase C-like triggered during a cell-cell contact.

Authors:  Nidia Alvarez-Rueda; Marlène Biron; Patrice Le Pape
Journal:  PLoS One       Date:  2009-10-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.